Vitrolife’s Q3 confirms that Vitrolife is going through a period with softer organic growth, even be...
Redeye returns with an updated take on the Q3 report.
Redey resumes coverage of Amniotics after the conclusion of the rights issue.
- EBITA beat and very strong cash flow... - ...mitigate concerns of high leverage - Adj.
Redeye returns with a research update on Nanologica following its Q3 2023 report, which were soft in...
- UK compensates for soft Swedish market - Announces potential next step in M&A strategy - We raise ...
Redeye provides an update following the Q3 report. Doro's performance exceeded our expectations, dri...
Redeye states that while the Q3 report was a clear dissapointment, the share-price reaction was over...
Redeye states the Q3 report is a good data point that the profitability "turn-around" story is under...
Redeye provides an update subsequent AVTECH's Q3 2023 report.
Redeye updates its estimates and valuation following ADDvise releasing its Q3 2023 report.
Redeye updates its estimates and valuation following Mentice’s Q3 2023 report.
Redeye comments on Medivir's Q3 report and on the new positive data from 18 patients in the liver ca...
CEPS up further on bond buybacks We expect acquisitions in the next ~6 months Valuation below the se...
Watch CEO Lars Lindell present the company’s Q3 report.
Panel discussion with Smart Eye and Acconeer. Watch the replay from October 26.
Another strong quarter, order intake up 33%, EBITA margin 9.
Suominen’s Q3 2023 results were an improvement from Q2, albeit slightly less than we and consensus h...
Redeye retains its positive view of Sdiptech following a Q3 report that exceeded our expectations.
Redeye has revised our estimates in light of Heliospectra’s Q3’23 report, which showed a suppressed ...
